NEWTON, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that management will provide an overview of the company during two upcoming investor conference presentations:
- Stifel 2015 Healthcare Conference in New York City on Wednesday, November 18, 2015 at 4:30 p.m. ET.
- Oppenheimer & Co. 26th Annual Healthcare Conference in New York City on Tuesday, December 8, 2015 at 8:00 a.m. ET.
A live and archived audio webcast of each presentation will be available under the News & Investors section of Chiasma's website at www.ChiasmaPharma.com.
Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company's lead product candidate is Mycapssa™ (octreotide capsules), a new investigational drug for the orphan condition acromegaly, developed with Chiasma's Transient Permeability Enhancer (TPE®) technology to facilitate gastrointestinal absorption of unmodified drug into the bloodstream safely. Mycapssa™ has not been approved for use in any jurisdiction. Using TPE® technology, Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery. TPE® technology is potentially well suited for drugs with chronic indications, where frequent dosing is required and the need for an oral alternative is greatest. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary.
Additional information can be found at www.ChiasmaPharma.com.
CONTACT: Jason Fredette Chiasma, Inc. (617) 928-5306 Jason.Fredette@ChiasmaPharma.comSource:Chiasma, Inc.